[go: up one dir, main page]

DE69400824D1 - Indol-derivate als 5-ht1-ähnliche antagonisten zur behandlung von migräne - Google Patents

Indol-derivate als 5-ht1-ähnliche antagonisten zur behandlung von migräne

Info

Publication number
DE69400824D1
DE69400824D1 DE69400824T DE69400824T DE69400824D1 DE 69400824 D1 DE69400824 D1 DE 69400824D1 DE 69400824 T DE69400824 T DE 69400824T DE 69400824 T DE69400824 T DE 69400824T DE 69400824 D1 DE69400824 D1 DE 69400824D1
Authority
DE
Germany
Prior art keywords
pct
antagonists
treating migraine
indol derivatives
date oct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69400824T
Other languages
English (en)
Other versions
DE69400824T2 (de
Inventor
Martin James Wythes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Research and Development Co NV SA
Original Assignee
Pfizer Research and Development Co NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939308360A external-priority patent/GB9308360D0/en
Priority claimed from GB939324433A external-priority patent/GB9324433D0/en
Application filed by Pfizer Research and Development Co NV SA filed Critical Pfizer Research and Development Co NV SA
Publication of DE69400824D1 publication Critical patent/DE69400824D1/de
Application granted granted Critical
Publication of DE69400824T2 publication Critical patent/DE69400824T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69400824T 1993-04-22 1994-04-11 Indol-derivate als 5-ht1-ähnliche antagonisten zur behandlung von migräne Expired - Fee Related DE69400824T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939308360A GB9308360D0 (en) 1993-04-22 1993-04-22 Indoles
GB939324433A GB9324433D0 (en) 1993-11-27 1993-11-27 Indoles
PCT/EP1994/001121 WO1994024127A1 (en) 1993-04-22 1994-04-11 Indole derivatives as 5-h1-like agonists for use in migraine

Publications (2)

Publication Number Publication Date
DE69400824D1 true DE69400824D1 (de) 1996-12-05
DE69400824T2 DE69400824T2 (de) 1997-03-13

Family

ID=26302791

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69400824T Expired - Fee Related DE69400824T2 (de) 1993-04-22 1994-04-11 Indol-derivate als 5-ht1-ähnliche antagonisten zur behandlung von migräne

Country Status (21)

Country Link
US (1) US5607960A (de)
EP (1) EP0695301B1 (de)
JP (1) JP2802169B2 (de)
KR (1) KR960701865A (de)
CN (1) CN1121348A (de)
AT (1) ATE144773T1 (de)
AU (1) AU6567094A (de)
BR (1) BR9406481A (de)
CA (1) CA2157397C (de)
CZ (1) CZ274595A3 (de)
DE (1) DE69400824T2 (de)
DK (1) DK0695301T3 (de)
ES (1) ES2094653T3 (de)
FI (1) FI954944A0 (de)
GR (1) GR3021804T3 (de)
HU (1) HUT73807A (de)
IL (1) IL109337A0 (de)
NO (1) NO954168D0 (de)
NZ (1) NZ265269A (de)
PL (1) PL311204A1 (de)
WO (1) WO1994024127A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
KR100191973B1 (ko) * 1993-08-31 1999-06-15 디. 제이. 우드, 스피겔 알렌 제이 5-아릴인돌 유도체
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9420503D0 (en) * 1994-10-11 1994-11-23 Pfizer Ltd Therapeutic agents
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
KR19980703048A (ko) * 1995-03-20 1998-09-05 피터쥐.스트링거 5-치환-3-(1,2,3,6-테트라히드로피리딘-4-일)- 및 3-(피페리딘-4-일)-1ｈ-인돌: 신규한 5-ｈｔ1ｆ 아고니스트
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
WO1998011895A1 (en) * 1996-09-18 1998-03-26 Eli Lilly And Company A method for the prevention of migraine
WO1998023587A1 (en) * 1996-11-26 1998-06-04 Allelix Biopharmaceuticals Inc. 5-cyclo indole compounds as 5-ht1d receptor ligands
US5998462A (en) * 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
US5856510A (en) * 1996-12-16 1999-01-05 Allelix Biopharmaceuticals Inc. 5-alkenyl and 5-alkynyl indole compounds
GB9705035D0 (en) * 1997-03-11 1997-04-30 Pharmacia & Upjohn Spa Indolyl-pyrrolydenemethylpyrrole derivatives and process for their preparation
EP0875513A1 (de) * 1997-04-14 1998-11-04 Eli Lilly And Company Substituierte heteroaromatische 5-HT1F Agoniste
WO1999007700A1 (en) * 1997-08-09 1999-02-18 Smithkline Beecham Plc Bicyclic compounds as ligands for 5-ht1 receptors
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6204274B1 (en) 1998-04-29 2001-03-20 American Home Products Corporation Indolyl derivatives as serotonergic agents
US6310066B1 (en) 1998-04-29 2001-10-30 American Home Products Corp. Antipsychotic indolyl derivatives
US6066637A (en) * 1998-06-19 2000-05-23 American Home Products Corporation Indolyl derivatives as serotonergic agents
WO2000000490A2 (en) * 1998-06-26 2000-01-06 Eli Lilly And Company 5-ht1f agonists
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
ES2219554T3 (es) 2000-07-21 2004-12-01 H. Lundbeck A/S Derivados de indol utiles en el tratamiento de desordenes del sistema nervioso central.
US6489512B1 (en) 2002-06-21 2002-12-03 Rhodia Chirex Inc. Method for making aryl hydrazines and substituted indoles
ATE350381T1 (de) * 2002-12-10 2007-01-15 Merck Patent Gmbh Indolderivate und deren verwendung als 5-ht liganden
CA2508290C (en) * 2002-12-20 2017-02-28 Ciba Specialty Chemicals Holding Inc. Synthesis of amines and intermediates for the synthesis thereof
MXPA05006954A (es) * 2002-12-26 2005-09-22 Pozen Inc Formas de dosificacion de capas multiples que contienen nsaids y triptanos.
CA2527368A1 (en) * 2003-06-06 2004-12-23 Glaxo Group Limited Pharmaceutical composition
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
WO2005066157A1 (en) * 2004-01-02 2005-07-21 Suven Life Sciences 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators
GB0807772D0 (en) * 2008-04-29 2008-06-04 Lectus Therapeutics Ltd Calcium ion modulators and uses thereof
FR2953720B1 (fr) * 2009-12-11 2012-05-11 Oreal Utilisation de derives de benzyloxy-ethylamines comme conservateur,
CN104557957B (zh) * 2013-10-09 2017-04-19 华东师范大学 螺‑氧化吲哚环氧乙烷衍生物的合成方法
BR112022015379A2 (pt) * 2020-02-04 2022-09-27 Mindset Pharma Inc Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc
WO2025021120A1 (zh) * 2023-07-24 2025-01-30 上海翊石医药科技有限公司 一类5-ht2a受体激动剂及其制备方法和应用
WO2025104491A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8530507D0 (en) * 1985-12-11 1986-01-22 Glaxo Group Plc Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
HU225055B1 (en) * 1990-10-15 2006-05-29 Pfizer Indole derivatives, their intermediates, process for production them and pharmaceutical compositions containing the compounds

Also Published As

Publication number Publication date
AU6567094A (en) 1994-11-08
JPH08507083A (ja) 1996-07-30
NO954168L (no) 1995-10-19
US5607960A (en) 1997-03-04
PL311204A1 (en) 1996-02-05
HUT73807A (en) 1996-09-30
GR3021804T3 (en) 1997-02-28
FI954944A7 (fi) 1995-10-17
KR960701865A (ko) 1996-03-28
CA2157397A1 (en) 1994-10-27
FI954944A0 (fi) 1995-10-17
NO954168D0 (no) 1995-10-19
NZ265269A (en) 1996-09-25
DK0695301T3 (da) 1996-12-09
IL109337A0 (en) 1994-07-31
CN1121348A (zh) 1996-04-24
EP0695301B1 (de) 1996-10-30
CA2157397C (en) 1999-07-06
ATE144773T1 (de) 1996-11-15
HU9501920D0 (en) 1995-09-28
ES2094653T3 (es) 1997-01-16
JP2802169B2 (ja) 1998-09-24
CZ274595A3 (en) 1996-03-13
EP0695301A1 (de) 1996-02-07
WO1994024127A1 (en) 1994-10-27
DE69400824T2 (de) 1997-03-13
BR9406481A (pt) 1996-01-09

Similar Documents

Publication Publication Date Title
DE69400824D1 (de) Indol-derivate als 5-ht1-ähnliche antagonisten zur behandlung von migräne
ES2121193T3 (es) Derivados de bencimidazoles.
DE59510635D1 (de) Verwendung heterocyclischer verbindungen als dopamin-d 3 liganden
NO20010446L (no) Substituert anilidforbindelser og metoder
ES2083595T3 (es) Derivados de indol que inhiben la biosintesis de leucotrienos.
ATE396722T1 (de) Kleine moleküle zur behandlung von endzündlichen erkrankungen
ATE320432T1 (de) Spiro-azacyclische derivate, deren herstellung und verwendung als tachykinin-antagonisten
DE69935670D1 (de) Behandlung von dyskinesie durch mu-selektive opioidantagonisten
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE253930T1 (de) Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)- aktivierungsweges
ATE354802T1 (de) Methoden zum screening knochenmorphogenetishemimetika
DE69819742D1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
DE59511073D1 (de) Agonisten und antagonisten der nicotinergen acetylcholinrezeptoren von insekten als endoparasitizide
DE69821142D1 (de) Verwendung von prostanoiden-antagonisten zur bhandlung von primären kopfschmerzen
DE69528288D1 (de) Indolderivate zur behandlung von migräne
DK0923549T3 (da) Methansulfonatsalt af et arylpiperazin afledt af tryptamin og solvater deraf til farmaceutisk anvendelse
MX9708966A (es) Sal fumarato de pirrolidinil metil indol, composicion que la contiene, procedimiento para su preparacion y uso de la misma.
ATE242212T1 (de) Benz(f)indole zur verwendung in der behandlung von 5ht-rezeptor relatierten störungen
ES2070087A1 (es) Derivados de indol

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee